Protein-based COVID-19 Vaccine Now Available at Thousands of Pharmacies

Novavax, Inc. today announced that doses of the Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) (NVX-CoV2705) to prevent COVID-19 in individuals aged 12 and older are in stock at major pharmacy retailers across the United States.

As of September 13, 2024, Novavax's updated protein-based vaccine is expected to be available in CVS Pharmacy, Rite Aid, Walgreens, Costco, Publix, Sam's Club, Kroger, Meijer, hundreds of other regional grocers and thousands of independent pharmacies.

Novavax's vaccine is the only protein-based option available in the fall season, and distribution locations are listed at us.novavaxcovidvaccine.com.

"We have worked hard to ensure greater ease of access for consumers this vaccination season by more than doubling the number of locations stocking our vaccine compared to last year and offering a more convenient presentation in a prefilled syringe," said John C. Jacobs, President, and Chief Executive Officer, Novavax, in a press release.

"Our vaccine targets JN.1, the 'parent strain' of those currently circulating, and our vaccine has demonstrated cross-reactivity against JN.1 lineage viruses, including KP.2.3, KP.3, KP.3.1.1 and LB.1.1."

Novavax's updated vaccine received Emergency Use Authorization on August 30, 2024, from the U.S. Food and Drug Administration.

"As of September 13, 2024, Novavax COVID-19 vaccine for individuals 12 and older is available at major pharmacy retailers across the U.S. in a prefilled syringe. And since Novavax is the only protein-based COVID-19 vaccine currently available, consumer demand may go up," says Jeanne Waggener, RPh.

"Novavax acts by targeting JN.1, the 'parent strain' of those viruses circulating. It also demonstrates cross-reactivity against the JN.1 lineage COVID viruses, including KP.2.3, KP.3, KP.3.1.1, and LB.1.1.," added Waggener, a Precision Vaccination News Contributing Expert.

Novavax is a global company advancing vaccines such as R21/Matrix-M™, which includes the company's proprietary saponin-based Matrix-M adjuvant and is licensed to and manufactured by the Serum Institute of India Private Ltd.

Note: Waggener Contributing Expert insight inserted on Sept. 17, 204.